Today's Veterinary Practice

NOV-DEC 2018

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link:

Contents of this Issue


Page 46 of 81

widely used. They would probably be appropriate only for cats with small, focal lesions and are not guaranteed to prevent progression. Because of the high rate of malignancy of posttraumatic ocular sarcomas in cats, any blind eye that resulted from trauma should be considered for early enucleation. After a sarcoma has developed, exenteration is the recommended treatment, along with staging to evaluate for involvement of the regional lymph nodes and for distant metastasis. CONCLUSION Intraocular neoplasia is uncommon in companion animals but should be considered in the differential diagnosis for patients with uveitis and glaucoma as well as for those with discrete masses. The most common primary intraocular tumor of both dogs and cats is uveal melanoma, although epithelial tumors and feline intraocular sarcomas are possible. Animals with bilateral disease should be evaluated for evidence of primary neoplasia elsewhere with metastatic spread to the eyes. For all species, knowing the most common tumor types and their appearance can help you determine the prognosis. Although the sequelae of tumor growth often necessitate enucleation of the affected eye, most primary intraocular neoplasia has low metastatic potential, so the overall prognosis for life is good. A good first-line tool for identifying intraocular masses is ultrasonography. When neoplasia is suspected, consider referring the patient to a veterinary ophthalmologist. For some patients, vision-sparing surgical procedures are available. Allison A. Fuchs Allison A. Fuchs, DVM, is an ophthalmology specialty intern at BluePearl Veterinary Partners in Atlanta. Her clinical interests include all aspects of veterinary ophthalmic disease, particularly ophthalmic manifestations of systemic diseases. She received her veterinary degree from Oklahoma State University and then completed a rotating internship with BluePearl Veterinary Partners in Atlanta. Ellen B. Belknap Ellen B. Belknap, DVM, MS, DACVIM, DACVO, is the ophthalmologist with BluePearl Veterinary Partners in Lawrenceville, Georgia. Dr. Belknap completed her veterinary degree at the University of Georgia and then a residency in large animal internal medicine at Michigan State University. She taught at Colorado State University and Auburn University before completing a residency in ophthalmology at Auburn University and Ohio State University. Dr. Belknap practiced in Akron, Ohio, before joining BluePearl in 2016. To see the references for this article, please visit . 30 mg/mL flavored solution in 10 mL, 15 mL and 30 mL bottles with measuring syringe For oral use in dogs only Appetite Stimulant Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Description: ENTYCE ® (capromorelin oral solution) is a selective ghrelin receptor agonist that binds to receptors and affects signaling in the hypothalamus to cause appetite stimulation and binds to the growth hormone secretagogue receptor in the pituitary gland to increase growth hormone secretion. Indication: ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs. Contraindications: ENTYCE should not be used in dogs that have a hypersensitivity to capromorelin. Warnings: Not for use in humans. Keep this and all medications out of reach of children and pets. Consult a physician in case of accidental ingestion by humans. For use in dogs only Precautions: Use with caution in dogs with hepatic dysfunction. ENTYCE is metabolized by CYP3A4 and CYP3A5 enzymes (See Clinical Pharmacology). Use with caution in dogs with renal insufficiency. ENTYCE is excreted approximately 37% in urine and 62% in feces (See Adverse Reactions and Clinical Pharmacology). The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches. Adverse Reactions: Field safety was evaluated in 244 dogs. The most common adverse reactions were diarrhea and vomiting. Of the dogs that received ENTYCE (n = 171), 12 experienced diarrhea and 11 experienced vomiting. Of the dogs treated with placebo (n = 73), 5 experienced diarrhea and 4 experienced vomiting. To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, call Aratana Therapeutics at 1-844-272-8262. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at Veterinary/SafetyHealth NADA 141-457, Approved by FDA US Patent: 6,107,306 US Patent: 6,673,929 Made in Canada Manufactured for: Aratana Therapeutics, Inc. Leawood, KS 66211 ENTYCE is a trademark of Aratana Therapeutics, Inc. © Aratana Therapeutics, Inc. AT2-021-16 August 2016 ®

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - NOV-DEC 2018